Patents Assigned to Cyclerion Therapeutics, Inc.
-
Patent number: 11834444Abstract: The present disclosure relates to novel processes for the preparation of compounds useful as stimulators of soluble guanylate cyclase (sGC). These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula (I), including Compound (I), Compound (IA) and Compound (IB), in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.Type: GrantFiled: July 6, 2017Date of Patent: December 5, 2023Assignee: Cyclerion Therapeutics, Inc.Inventors: Song Xue, Vishnu Vardhan Reddy Karnati, Robert C. Livingston, Timothy Claude Barden, Wayne C. Schairer
-
Publication number: 20230372335Abstract: The present invention relates to a method of treating cognitive impairment in a patient in need thereof by administering Compound (I), a stimulator of soluble guanylate cyclase (sGC) at certain dosages either alone or in combination therapy.Type: ApplicationFiled: October 12, 2021Publication date: November 23, 2023Applicant: Cyclerion Therapeutics, Inc.Inventors: Christopher John Winrow, Christopher Ian Wright, Chad Edward Glasser, Phillip M. Alday, Alexander Ross Arslan, David F. Kleinschmidt, Jacob Donoghue
-
Patent number: 11773089Abstract: The present disclosure relates to novel processes for the preparation of compounds useful as stimulators of soluble guanylate cyclase (sGC). These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula (I), including Compound (I), in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.Type: GrantFiled: March 30, 2022Date of Patent: October 3, 2023Assignee: Cyclerion Therapeutics, Inc.Inventors: Song Xue, Vishnu Vardhan Reddy Karnati, Robert C. Livingston
-
Patent number: 11731977Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.Type: GrantFiled: September 27, 2021Date of Patent: August 22, 2023Assignee: Cyclerion Therapeutics, Inc.Inventors: Glen Robert Rennie, Rajesh R. Iyengar, Thomas Wai-Ho Lee, Paul Allan Renhowe, Joon Jung, Kim Tang
-
Patent number: 11708361Abstract: The present disclosure relates to novel processes for the preparation of compounds of Formula I. Some of these compounds are useful as stimulators of soluble guanylate cyclase (sGC). Others are useful intermediates towards the preparation of said stimulators. These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula I in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.Type: GrantFiled: October 8, 2021Date of Patent: July 25, 2023Assignee: Cyclerion Therapeutics, Inc.Inventors: Debra Jane Wallace, Fenger Zhou, Yuguang Wang, Takashi Nakai, Vishnu Vardhan Reddy Karnati, Wayne C. Schairer, William Kissel, Song Xue, Ahmad Hashash
-
Patent number: 11690828Abstract: The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3?,5?-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.Type: GrantFiled: November 7, 2017Date of Patent: July 4, 2023Assignee: Cyclerion Therapeutics, Inc.Inventors: Joon Jung, Thomas Wai-Ho Lee, Rajesh R. Iyengar, Nicholas Robert Perl, Peter Germano, Maria D. Ribadeneira, Kim Tang
-
Patent number: 11572358Abstract: The present disclosure relates to crystalline solid forms of a stimulator of soluble guanylate cyclase (sGC), Compound I: Also provided herein are methods for the preparation of these solid forms. The invention also relates to pharmaceutical formulations and dosage forms comprising these solid forms and their uses thereof, alone or in combination with one or more additional agents, for treating and/or preventing various diseases or disorders; these diseases or disorders are ones that may benefit from sGC stimulation or from an increase in the concentration of nitric oxide (NO) and/or cyclic guanosine monophosphate (cGMP).Type: GrantFiled: December 29, 2020Date of Patent: February 7, 2023Assignee: Cyclerion Therapeutics, Inc.Inventors: Vasu Sethuraman, Ahmad Hashash, Song Xue, Robert C. Livingston, Kwame Wiredu Nti-Addae
-
Patent number: 11466015Abstract: The present disclosure relates to crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine, depicted below as a compound of Formula (I): which are useful as a stimulator of soluble guanylate cyclase (sGC). The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline forms and methods of using said compositions in the treatment of various disorders.Type: GrantFiled: March 7, 2019Date of Patent: October 11, 2022Assignee: Cyclerion Therapeutics, Inc.Inventors: Kwame W. Nti-Addae, Leena Kumari Prasad, Thomas Storz
-
Patent number: 11466014Abstract: The invention relates to novel methods for preparing 3-substituted 1,2,4-triazole compounds of Formula IA: as sGC stimulators. The method comprises reacting the amidrazone compound represented by Formula IIA: or a salt thereof, with a carboxylic acid, an activated ester, a thioester, an acid halide, a thioacyl halide, or an acid anhydride in the presence of a base.Type: GrantFiled: March 7, 2019Date of Patent: October 11, 2022Assignee: Cyclerion Therapeutics, Inc.Inventor: Thomas Storz
-
Patent number: 11389449Abstract: The present invention provides a method of treating a subject with metabolic syndrome by administering a stimulator of soluble guanylate cyclase (sGC) (Compound I) either alone or in combination therapy with a blood glucose lowering (antihyperglycemic or antidiabetes) medication, a blood pressure lowering (anti-hypertensive) medication, an anti-hyperlipidemic medication, or combinations thereof.Type: GrantFiled: September 14, 2018Date of Patent: July 19, 2022Assignee: Cyclerion Therapeutics, Inc.Inventors: John P. Hanrahan, Albert Thomas Profy, James D. Wakefield
-
Patent number: 11357777Abstract: The present disclosure relates to methods, uses, pharmaceutical compositions and kits comprising an sGC stimulator or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for the treatment of Nonalcoholic Steatohepatitis (NASH).Type: GrantFiled: January 31, 2017Date of Patent: June 14, 2022Assignee: Cyclerion Therapeutics, Inc.Inventors: G-Yoon Jamie Im, Mark G. Currie, James Edward Sheppeck, Paul Allan Renhowe, Pei Ge, Jaime L. Masferrer
-
Patent number: 11319308Abstract: The present disclosure relates to novel processes for the preparation of compounds useful as stimulators of soluble guanylate cyclase (sGC). These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula (I), including Compound (I), in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.Type: GrantFiled: July 6, 2017Date of Patent: May 3, 2022Assignee: Cyclerion Therapeutics, Inc.Inventors: Song Xue, Vishnu Vardhan Reddy Karnati, Robert C. Livingston
-
Patent number: 11274096Abstract: The present disclosure relates to novel processes for the preparation of compounds of Formula I. Some of these compounds are useful as simulators of soluble guanylate cyclase (sGC). Others are useful intermediates towards the preparation of said simulators. These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula I in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.Type: GrantFiled: January 10, 2019Date of Patent: March 15, 2022Assignee: Cyclerion Therapeutics, Inc.Inventors: Debra Jane Wallace, Fenger Zhou, Yuguang Wang, Takashi Nakai, Vishnu Vardhan Reddy Karnati, Wayne C. Schairer, William Kissel, Song Xue, Ahmad Hashash
-
Patent number: 11207323Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.Type: GrantFiled: March 13, 2020Date of Patent: December 28, 2021Assignee: Cyclerion Therapeutics, Inc.Inventors: Takashi Nakai, Joel Moore, Nicholas Robert Perl, Rajesh R. Iyengar, Ara Mermerian, G-Yoon Jamie Im, Thomas Wai-Ho Lee, Colleen Hudson, Glen Robert Rennie, Lei Jia, Paul Allan Renhowe, Timothy Claude Barden, Xiang Y. Yu, James Edward Sheppeck, Karthik Iyer, Joon Jung, George Todd Milne, Kimberly Kafadar Long, Mark G. Currie
-
Patent number: 11180493Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I).Type: GrantFiled: November 7, 2017Date of Patent: November 23, 2021Assignee: Cyclerion Therapeutics, Inc.Inventors: Glen Robert Rennie, Timothy Claude Barden, Thomas Wai-Ho Lee, Rajesh R. Iyengar, Takashi Nakai, Ara Mermerian, Lei Jia, Karthik Iyer, G-Yoon Jamie Im, Paul Allan Renhowe, Joon Jung, Peter Germano, Kim Tang
-
Patent number: 10927136Abstract: The present patent application discloses the compounds according to Formula (I) shown below, or pharmaceutically acceptable salts thereof wherein JB, n, R1, R2, R3, R4, R5, m and X as defined herein.Type: GrantFiled: July 6, 2017Date of Patent: February 23, 2021Assignee: Cyclerion Therapeutics, Inc.Inventors: James Edward Sheppeck, Paul Allan Renhowe, Ara Mermerian, Timothy Claude Barden, Glen Robert Rennie, Rajesh R. Iyengar, Takashi Nakai
-
Patent number: 10889577Abstract: The present disclosure relates to crystalline solid forms of a stimulator of soluble guanylate cyclase (sGC), Compound I: Also provided herein are methods for the preparation of these solid forms. The invention also relates to pharmaceutical formulations and dosage forms comprising these solid forms and their uses thereof, alone or in combination with one or more additional agents, for treating and/or preventing various diseases or disorders; these diseases or disorders are ones that may benefit from sGC stimulation or from an increase in the concentration of nitric oxide (NO) and/or cyclic guanosine monophosphate (cGMP).Type: GrantFiled: July 6, 2017Date of Patent: January 12, 2021Assignee: Cyclerion Therapeutics, Inc.Inventors: Vasu Sethuraman, Ahmad Hashash, Song Xue, Robert C. Livingston, Kwame Wiredu Nti-Addae
-
Patent number: 10858363Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.Type: GrantFiled: February 12, 2019Date of Patent: December 8, 2020Assignee: Cyclerion Therapeutics, Inc.Inventors: Glen Robert Rennie, Rajesh R. Iyengar, Thomas Wai-Ho Lee, Takashi Nakai, Ara Mermerian, Lei Jia, G-Yoon Jamie Im, Paul Allan Renhowe, Joon Jung, Peter Germano, Karthik Iyer, Timothy Claude Barden, Kim Tang
-
Patent number: 10844064Abstract: The present patent application discloses at least the compounds according to Formula I? shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, JB, n, JD, J, X, Z, Z1, RC1, RC2, Y, R9, o and W are as defined herein.Type: GrantFiled: September 16, 2015Date of Patent: November 24, 2020Assignee: Cyclerion Therapeutics, Inc.Inventors: Glen Robert Rennie, Nicholas Perl, Ara Mermerian, Joon Jung, Lei Jia, Rajesh R. Iyengar, G-Yoon Jamie Im, Timothy Claude Barden, James Edward Sheppeck, Paul Allan Renhowe, Takashi Nakai, Thomas Wai-Ho Lee, Karthik Iyer
-
Patent number: 10639308Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.Type: GrantFiled: November 2, 2018Date of Patent: May 5, 2020Assignee: Cyclerion Therapeutics, Inc.Inventors: Takashi Nakai, Joel Moore, Nicholas Robert Perl, Rajesh R. Iyengar, Ara Mermerian, G-Yoon Jamie Im, Thomas Wai-Ho Lee, Colleen Hudson, Glen Robert Rennie, Lei Jia, Paul Allan Renhowe, Timothy Claude Barden, Xiang Y. Yu, James Edward Sheppeck, Karthik Iyer, Joon Jung, George Todd Milne, Kimberly Kafadar Long, Mark G. Currie